Product Information
ACAMPROSATE CALC DR 333 MG TAB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.5891 per EA under NDC 00378633380. Its NADAC has been published 621 times since Nov 12, 2014.
FDA first approved this application on Mar 11, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
333 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378633380
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACAMPROSATE CALCIUMApproval Type
Generic (ANDA)
FDA Application
ANDA200142FDA Approved
3/11/2014
TE Code
AB
On Market Since
9/24/2014
Price Statistics
The NADAC for ACAMPROSATE CALC DR 333 MG TAB has been published 621 times since Nov 12, 2014, and over the history we have for it it has declined 20.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5891 per EA |
|---|---|
| All-time high | $1.1432 (Aug 10, 2016) |
| All-time low | $0.2971 (Nov 20, 2024) |
| 52-week high | $0.6218 |
| 52-week low | $0.5871 |
| Median price | $0.6785 |
| Average price | $0.6744 |
| Largest weekly change | +76.4% (Feb 12, 2025) |
| Weeks tracked | 621 |
| Tracking since | Nov 12, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the acamprosate calcium enteric-coated market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
acamprosate calcium enteric-coated market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACAMPROSATE CALC DR 333 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for ACAMPROSATE CALC DR 333 MG TAB, manufactured by Mylan Pharmaceuticals Inc., is $0.5891 per EA (NDC 00378633380), effective Sep 30, 2026.
How has the price of ACAMPROSATE CALC DR 333 MG TAB changed over time?
Over the history we have for it, the NADAC for ACAMPROSATE CALC DR 333 MG TAB has declined 20.7%. It has been tracked across 621 weekly CMS publications since Nov 12, 2014.
What are the highest and lowest recorded NADAC prices for ACAMPROSATE CALC DR 333 MG TAB?
Since Nov 12, 2014, the NADAC for ACAMPROSATE CALC DR 333 MG TAB has ranged from a low of $0.2971 (Nov 20, 2024) to a high of $1.1432 (Aug 10, 2016), with a median of $0.6785 per EA.
Are there cheaper alternatives to ACAMPROSATE CALC DR 333 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of ACAMPROSATE CALC DR 333 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ACAMPROSATE CALC DR 333 MG TAB?
ACAMPROSATE CALC DR 333 MG TAB (NDC 00378633380) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.